Avadel Pharmaceuticals PLC
As filed: AVADEL PHARMACEUTICALS PLC
Every mark, and where it comes from
Each row is one fund's own reported figure for 2026-Q2. "Per share" is the reported dollar value divided by the reported share count — nothing else has been done to it. The filing link opens the document the two numbers came from.
| Fund | Instrument | Shares | Value | Per share | % of fund | As of | Filing |
|---|---|---|---|---|---|---|---|
Franklin Small Cap Enhanced ETF Franklin Templeton ETF Trust | ALKERMES PLC | 34,399 | $22,015 | $0.6400 | 0.02% | 2026-06-30 | 0000940400-26-035101 |
Franklin U.S. Small Cap Equity Fund Legg Mason Global Asset Management Trust | ALKERMES PLC | 15,064 | $9,641 | $0.6400 | 0.01% | 2026-06-30 | 0000940400-26-034755 |
VIP Disciplined Small Cap Portfolio Variable Insurance Products Fund II | AVADEL PHARMACEUTICALS PLC CVR RT | 17,082 | $0 | $0.0000 | 0.00% | 2026-06-30 | 0000035402-26-005552 |
These funds hold 2 different instruments in Avadel Pharmaceuticals PLC. Different preferred series carry genuinely different rights and prices, so part of the spread above is not disagreement about the company — it is the difference between the securities. Compare rows with the same instrument before drawing a conclusion.
Can you actually own any of this?
No public company discloses a stake in Avadel Pharmaceuticals PLC, and no fund we can price holds it. For an investor without accredited status there is no position to take here at all — the marks above are information, not an opportunity. That is a more useful conclusion than it looks: it is the gap that products promising retail "pre-IPO access" are sold into. See which companies do have routes.
How accurate have marks like these been?
Avadel Pharmaceuticals PLC is still private, so nothing here can be scored against a market price yet. What can be scored is the method: 6 companies we covered have since listed. On the 3 of those whose share count did not change on the way to market, the median fund mark came in -38.2% against the first closing price, with a worst absolute miss of 2250%. Marks are consistently conservative and occasionally very wrong. Every graded listing is published, including the ones that make the method look bad.
How to read this without being misled
This is not what a share of Avadel Pharmaceuticals PLC trades at. Funds here hold preferred stock bought in a funding round, and they carry it at what their valuation committee believes it is worth — usually anchored near what they paid. Common stock sold by employees on a secondary market can trade well above or below it. The two numbers answer different questions.
A median is not a consensus. With 3 funds and a 100% spread, the median is a summary of a small sample, not a market price. The table above is the data; the median is a convenience.
Marks lag. The figures are as of 2026-06-30, filed weeks later. A round or a markdown after that date is not in here yet.
You probably cannot buy this. Shares in Avadel Pharmaceuticals PLC are not available to an individual investor on any ordinary brokerage, and the funds above bought theirs in private rounds. A mark is information about what regulated investors think a stake is worth — not a route to owning one.
Learn to read these filings yourself
Seven free lessons on where a private valuation comes from, how wrong they turn out to be, what the public routes really cost, and how a lock-up expiry works. Every figure computed from the same filings as this page.
Snapshot built 2026-11-07 from SEC EDGAR · all covered companies · this company as JSON